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Background: Varicose veins can affect quality of life. Patient-reported outcome measures (PROMs) 
provide a direct report from the patient about the impact of the disease without interpretation from 
clinicians or anyone else. The aim of this study was to examine the quality of the psychometric 
evidence of PROMs used in patients with varicose veins.  
Methods: A systematic review was undertaken to identify studies that reported the psychometric 
properties of generic and disease-specific PROMs in patients with varicose veins. Literature searches 
were conducted in databases including MEDLINE, up to July 2016. The psychometric criteria used to 
assess these studies were adapted from published recommendations in accordance with US Food and 
Drug Administration guidance.  
Results: Nine studies were included which reported on aspects of the development and/or validation 
of one generic (36-Item Short Form Survey, SF-36®) and three disease-specific (Aberdeen Varicose 
Vein Questionnaire, AVVQ; Varicose Veins Symptoms Questionnaire, VVSymQ®; Specific Quality-
of-life and Outcome Response ± Venous, SQOR-V) PROMS. The evidence from included studies 
provided data to support the construct validity, internal consistency  and responsiveness of the 
AVVQ; this instrument also had test±retest reliability (intraclass correlation coefficient 0.59). 
However, its content validity, including weighting of the AVVQ questions, was biased and based on 
the opinion of clinicians, and the instrument had poor acceptability. VVSymQ® displayed good 
responsiveness and acceptability rates. SF-36® was considered to have satisfactory responsiveness and 
internal consistency (Cronbach¶V Į = 0.80). 
Conclusion: There is a scarcity of psychometric evidence for PROMs used in patients with varicose 
veins. These data suggest that AVVQ and SF-36® are the most rigorously evaluated PROMs in 
patients with varicose veins.   
 
 
 
 
 
+A: Introduction 
 
Varicose veins are enlarged lumpy visible veins caused by reflux of blood in the superficial veins of 
the leg1. They are extremely common, affecting more than half of the population in Western Europe 
and North America2±4. Varicose veins can cause symptoms such as pain, aching, swelling, throbbing, 
cramping, itching and bleeding5. Complications include superficial thrombophlebitis, external 
bleeding, lipodermatosclerosis, eczema and ulceration6,7. Traditionally, treatment comprised surgery 
with stripping of the great saphenous vein and removal of the varicose veins through small incisions 
(avulsions or phlebectomies). However, in the past decade new less invasive treatments have been 
developed8. In 2009±2010, 35 659 varicose vein procedures were carried out in the National Health 
Service (NHS)8.  
Patient-reported outcome measures (PROMS) provide a means by which the impact of 
varicose veins or their treatments on quality of life can be measured. The questionnaires are typically 
developed from qualitative studies involving patients and clinicians. The items in these questionnaires 
are then WHVWHG IRU WKHLU DELOLW\ WR FDSWXUH WKH SDWLHQW¶V H[SHULHQFH LQ SURVSHFWLYH VXUYH\V, using 
psychometric analyses to explore the relationship of the items with each other and their overall ability 
to detect change9. The NHS PROMS programme has been collecting PROMs data from patients 
undergoing varicose vein interventions since April 2009 using generic and disease-specific PROMS10.  
The aim of this study was to identify and examine the quality of the psychometric evidence 
for PROMs used for patients with varicose veins. This study was divided into two parts; initially a 
systematic review was undertaken to identify the appropriate papers, and then a psychometric 
assessment was undertaken to assess the quality of the methods used to validate or design these 
PROMs.  
+A: Methods 
A systematic review was undertaken and reported in accordance with the general principles 
recommended in PRISMA statement11.  The protocol for the systematic review was developed and 
registered in the PROSPERO international prospective register of systematic reviews before the start 
of the data extraction12. 
Systematic searches were undertaken in MEDLINE and MEDLINE In-Process, Embase, the 
Cochrane Library, CINAHL, PROQOLID, PsycINFO and Web of Science.  A two-stage search 
approach was used. The first stage used general terms for PROMs (known generic and condition-
specific PROMS) and terms for the condition (varicose veins) to identify studies.  These were 
retrieved, and the title and abstract examined for additional PROM terms used in patients with 
varicose veins.  The second stage incorporated these terms with the preliminary search strategy and a 
methodological search filter for finding studies on measurement properties. Databases were searched 
from inception up to July 2016 for search 1 and up to July 2016 for search 2. Searches were 
supplemented by hand-searching reference lists of relevant reviews and included studies, citation 
search of included studies and contact wiWK H[SHUWV LQ WKH ¿HOG  Search strategies are shown in 
(Appendix S1, supporting information) 
+B: Study selection 
The titles were reviewed, and the abstracts and full text of the included articles were assessed by at 
least two reviewers independently.  Any disagreements in the selection process were resolved by 
discussion, with involvement of a third reviewer.  Eligible studies included articles published in 
English of any study design that reported the validation or development of PROMs capturing quality 
of life, health status or functional limitation in patients with varicose veins in an English-speaking 
population (Table 1). 
+B: Data abstraction  
Data relating to study design, patient characteristics, type of treatment, PROM used, methods and 
outcomes were extracted by one reviewer on to a standardized data extraction form, and 
independently checked for accuracy by a second. Any discrepancies were resolved by discussion, with 
involvement of a third reviewer. Where necessary, study authors were contacted for missing 
information or additional data.   
+B: Methodological quality assessment (psychometric evaluation) 
The methodological quality assessment in developing the PROMs was based on specific psychometric 
criteria. Owing to lack of consensus on how to appraise PROMs, the study-specific criteria were 
adapted from published recommendations13±16,18 in accordance with the US Food and Drug 
Administration (FDA) guidance 200917. They were mainly based on the Oxford University PROMs 
Group guidelines and the COnsensus-based Standards for the selection of health status Measurement 
INstruments (COSMIN)19. These criteria can be divided into four areas: reliability, validity, 
responsiveness and acceptability (Table 2). Two independent researchers appraised these 
psychometric properties for each PROM independently using the following methods of assessment. A 
rating scale was designed to allocate a mark for each domain:  0, not reported;  ±, evidence not in 
favour; +/±, conflicting evidence; and +, evidence in favour. Any disagreements were resolved 
through discussion or with involvement of a psychometrics expert.  
+C: Assessment of reliability 
The reliability of a PROM is its ability to produce the same results when measurements are repeated 
in populations with similar characteristics20. The reliability of each identified PROM was assessed by 
examining the reported data on reproducibility and internal consistency. The reproducibility of an 
instrument is commonly examined by performing test±retest at different time points. The degree of 
correlation is examined between the scores at baseline and those at different time points. PROMs 
should report test±retest using the intraclass correlation or weighted Nscore; this should be at least 
0.70 for group comparisons20.  
PROMs commonly use more than one item to measure a single dimension that is important to 
the patient; this is because several related observations can produce a better estimate than one. These 
items need to be homogeneous; this means that they all measure aspects of a single attribute rather 
than different ones and are therefore internally consistent13. Internal consistency is usually measured 
XVLQJ&URQEDFK¶VD, which should have a value of more than 0.70 and below 0.90 for the proposed 
PROM to be psychometrically sound13,23. 
+C: Assessment of validity  
Validity is the measure of how well a PROM measures what it is intended to measure. Validity was 
assessed for each identified PROM by assessing content validity, construct validity and criterion 
validity. Content validity was measured by examining the relevance of the items in the PROM to their 
intended use. This was assessed on the basis of whether these items were developed through 
qualitative studies with patient groups involving clinicians and incorporating published evidence23. 
Criterion validity is concerned with assessing the PROM in question against a standard PROM that 
provides a benchmark of the true values. The new PROM should demonstrate correlation coefficient 
scores of more than 0.70. However, in reality this is often very difficult to assess in the absence of 
such a standard14,15.  
+C: Assessment of responsiveness 
This is defined as the ability of a PROM to detect clinically important change over time, if a true 
change exists.  The PROM should be able to distinguish between clinically important changes and 
measurement error. Responsiveness of a measure can be calculated using methods such as use of 
standardized response means, t WHVWHIIHFWVL]HDQG*X\DWW¶VUHVSRQVLYHQHVVUDtio21,22,24. 
+B: Assessment of acceptability and floor or ceiling effect  
Acceptability is measured by the completeness of the data. For a PROM to show a good level of 
acceptability, 80 per cent or more of the data should be complete when the PROM is administered to 
the patients19. A floor or ceiling effect is considered if 15 per cent of respondents are achieving the lowest or 
the highest score on the instrument. 
+A: Results 
 
A total of 3647 records were identified; following detailed examination, nine studies25±33 (reporting on 
4 PROMs) were included (Fig. 1). PROMs that were not specific for varicose veins and examined 
chronic venous disease in general were excluded; examples of these are the ChronIc Venous 
Insufficiency quality of life Questionnaire (CIVIQ) 20 and CIVIQ-14, both chronic venous disease 
PROMS, and the Venous Insufficiency Epidemiologic and Economic Study ± Quality of 
Life/Symptoms (VEINES-QOL/Sym), a PROM validated in patients with deep venous thrombosis 
and venous leg ulcers. 
All the included studies assessed the psychometric properties and suitability of the suggested 
PROMs in patients with varicose veins (Table 3). The studies were prospective in design, and were 
undertaken in the UK and USA.  They were published between 1992 and 2016. The majority of the 
studies were of a small to moderate size with the number of patients ranging from 4033 to 170024,25. 
Patients aged between 16 and 86 years were recruited in the included studies, with the proportion of 
men ranging from 24 per cent24 to 47.6 per cent27.  
+B: Patient-reported outcomes measurement data and psychometric evaluation  
Overall, data relating to the development and psychometric evaluation of one generic PROM and 
three condition-specific PROMs for patients with varicose veins were available. The only generic 
PROM evaluated was the 36-Item Short Form Health Survey (SF-36®)25,27. The condition-specific 
PROMs were the Aberdeen Varicose Vein Questionnaire (AVVQ)26,28±30, the Varicose Veins 
Symptoms Questionnaire (VVSymQ®) and the Specific Quality-of-life and Outcome Response 
(SQOR-V)31,32. 
The protocol regarding timing of PROMs differed between the studies. The shortest follow-up 
was immediately following the intervention and the longest was 12 months after treatment. The rigour 
of the psychometric assessment of the PROMs was variable. The AVVQ was the only instrument 
evaluated in detail, with assessment of all the important psychometric domains were assessed (Table 
4.)  
+C: Short Form Health Survey 36  
 
Garratt and colleagues25±28 assessed aspects of the psychometric validity of this generic instrument in 
patients with varicose veins. In a study of 1700 patients, including 314 with varicose veins, the SF-
36® was examined for its suitability as a PROM for patients treated in the NHS. The internal 
consistency was assessed using two techniques, LWHP VFDOH FRUUHODWLRQ DQG &URQEDFK¶VD. The first 
method examined the extent to which an item was related to the rest of the scale, ZKHUHDV&URQEDFK¶V
D measured the overall correlation between items in the scale. The correlation for all items was above 
the 0.4, SURYLGLQJ HYLGHQFH RI LQWHUQDO FRQVLVWHQF\ 7KH &URQEDFK¶V D value exceeded 0.8 and 
satisfied the criteria for internal consistency. The response rate for SF-36® in this study at baseline 
was 75.5 per cent, showing some evidence of acceptability for this PROM; however, this dropped to 
67.5 per cent after 1 year. The construct validity assessment used ordinary least regression to estimate 
the effect on each scale in the PROM of varicose veins, age, sex and socioeconomic status of the 
participants.   The impact of varicose veins was significant only on the physical functioning scale. The 
responsiveness of SF-36® was assessed in the same population after 12 months, with results showing 
good responsiveness for this PROM. The standardized response mean was used to measure this 
property, and patients with varicose veins had a significantly higher level of improvement across the 
SF-36® scales at 1 year than those not referred for treatment.  
+C: Aberdeen Varicose Vein Questionnaire  
  
This disease-specific PROM was developed by Garratt et al.25, and the items were generated based on 
questions commonly used to assess patients with varicose veins. The items generated were confirmed 
by two clinicians and then pretested in patients for relevance and validity25. The AVVQ was tested for 
internal consistency, construct and criterion validity, and acceptability. The result of internal 
consistency evaluation DIWHUUHPRYLQJILYHTXHVWLRQVWKDWGLGQRWIXOILOWKHFULWHULDZDVD&URQEDFK¶VD 
value of 0.72, satisfying the psychometric criterion for this PROM34. The construct validity of the 
instrument was tested using stepwise multiple regression and comparison with the Varicose Vein 
Severity Score. The regression model confirmed that AVVQ explains a substantial proportion of the 
non-random variation in the patieQWV¶SHUFHLYHGKHDOWKThe AVVQ showed high acceptability among 
patients with 76 per cent complete data when the PROM was administered25. Comparing to eight 
scales of the SF-36 in patients with varicose veins assessed the criterion validity of the AVVQ; the 
AVVQ achieved highly negative correlations with all eight scales of the SF-3628. Four of these 
correlations exceeded 0.4, including physical functioning, pain, social functioning and role 
limitations. These correlations suggest that AVVQ can pick up adverse effects of varicose veins better 
than the generic PROM SF-36®. The test±retest reliability assessment of this PROM showed an 
intraclass correlation coefficient of above 0.7 in all domains except one, in which patients reported no 
change in symptoms after 1 year. The responsiveness of the AVVQ to changes in health over time 
was assessed by administering the questionnaire to the same respondents after 1 year28. In an analysis 
of standardized response means over 1 year, all items showed improvement, especially for patients 
who received treatment; patients not referred to a specialist had lower perceived health compared with 
the general population28. 
Lattimer and colleagues30 attempted to examine the responsiveness of the AVVQ in patients 
receiving endogenous laser ablation or foam sclerotherapy for varicose veins as part of an RCT. The 
patients included in the study all had primary disease with no previous intervention. The Wilcoxon 
signed-rank test was used to compare differences within the same group before and after intervention. 
Spearman¶V U was used to assessed the correlation between the severity of symptoms and AVVQ 
outcomes. The study reported improved AVVQ score after 3 weeks and 3 months of follow-up29,30.  
Varicose Veins Symptoms Questionnaire  
 
This electronic PROM was developed in accordance with the FDA guidance16. This included 
qualitative studies that involved patients to generate the five items in the PROM, all related to 
symptoms alone. The psychometric properties were examined as part of two RCTs (VANISH-1 and 
VANISH-2) evaluating microfoam ablation with varying does of polidocanol endovenous microfoam 
in patients with varicose veins31,33. The test±retest reliability was examined using intraclass correlation 
coefficients to assess whether VVSymQ® yielded a reproducible score in patients exhibiting no 
change in health status. The reported intraclass correlation coefficient was 0.75, demonstrating 
acceptable test±retest reliability. Cronbach¶VD value was 0.76 showing good internal consistency of 
the items included in the PROM. The construct validity was evaluated through Pearson correlation 
analyses; the score from the PROM showed correlations with reported clinical outcomes31. The 
VVSymQ® score captured meaningful clinical change and treatment impact, with an effect size of 1.6 
when the scores were compared between baseline and 6 weeks after intervention. This electronic 
PROM had between 86.1 and 97 per cent data completion, reflecting good acceptability among the 
patients31,33. 
+C: Specific Quality-of-life and Outcome Response ± Venous  
This instrument consists of 46 items divided into five domains: physical discomfort, appearance, 
restriction in movement, emotional problems and threat to health. All patients in the study32 
underwent radiofrequency ablation. The performance of the PROM was tested against the AVVQ and 
other clinical outcomes. The scores from the AVVQ and SQOR-V showed strong positive correlation 
with a Spearman coefficient of 0.702 (P < 0.001). Responsiveness was tested at 6 weeks, with poor 
results for SQOR-V in some patient groups compared with the AVVQ. The acceptability, as measured 
by the completeness of the data, was weak (67 per cent complete data) 32.  
+A: Discussion  
 
This study identified PROMs that have undergone validation in patients with varicose veins, and 
assessed the methodology of psychometric validation in accordance with FDA guidance, Oxford 
PROMS group guidelines and COSMIN13±19. Patient-reported outcome is an important core outcome 
recommended to be collected as part of service analysis and clinical studies35±37. Clinicians and 
researchers are faced with a dilemma when deciding on the instrument that measures this outcome. In 
the UK NHS, the measures used to collect data on PROMs for patients undergoing surgical 
management for varicose veins are the AVVQ and EuroQoL Five Dimensions (EQ-5D; EuroQol 
Group, Rotterdam, The Netherlands38.  
This review identified only one generic measure (SF-36®) and three disease-specific 
instruments (AVVQ, VVSymQ®, SQOPR-V) that have undergone psychometric assessment in 
patients with varicose veins. The evidence suggests that the SF-36® exhibits good internal consistency 
and acceptability among patients with varicose veins, with some evidence of construct validity and 
responsiveness. The AVVQ had good test±retest reliability, construct and criterion validity, and 
responsiveness. However, the evidence for the content validity was weak, and clinicians and 
researchers generated the items with limited input from patients; the weighting of the items was based 
on the judgement of two clinicians.  VVSymQ® had good internal consistency, test±retest reliability, 
construct, content and criterion validity, and responsiveness.  The acceptability of the VVSymQ® was 
better than that of the AVVQ and SF-36®; this is in part because it is an electronic questionnaire; 
however, the only domain in this instrument is symptoms.  
   The main strength of this study was the use of comprehensive search strategies to identify all 
relevant papers that reported on psychometric validation of PROMs for patients with varicose veins. 
The psychometric assessment domains in this study were based on different but overlapping 
psychometric evaluation criteria16,17,19,38. The main limitation of the analysis was the heterogeneity of 
the patients included in the studies as well as the different protocols for administering the PROMs. 
Furthermore, the content validity of the disease-specific measures was based on information limited to 
either that gathered by consulting patients about items generated by researchers and clinicians, or data 
from small qualitative research studies, with no systematic review of the qualitative evidence25,27±31,33. 
None of the studies included in the review provided any information on how they dealt with missing 
data.  
The only generic PROM with psychometric evidence to support its use in patients with 
varicose veins was the SF-36®; no data on the EQ-5D were found. The AVVQ was the most 
evaluated disease-specific PROM, with five studies examining its psychometric validity. Further work 
is needed to improve the content validity and acceptability of PROMs used in patients with varicose 
veins. The authors also recommend further research on the use of electronic PROMs based on the 
acceptability data for the VVSymQ®.  
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Fig. 1 PRISMA diagram showing selection of studies for review of patient-reported outcome measures (PROMs) in patients 
with varicose veins  
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Table 1 Criteria for considering eligibility of studies 
 
 Inclusion criteria Exclusion criteria 
Population A defined population of English-speaking 
participants with a diagnosis of 
varicose veins 
 
Undefined population of patients with 
chronic venous disease 
or  
Non-English-speaking patients with 
varicose veins 
Interventions No intervention or any intervention 
indicated for varicose veins 
 
Outcomes PROMS covering  any of the following: 
generic or  preference-based measures 
e.g. EQ-5D, SF-6D, SF-36®; 
directly elicited preference-based 
measures, e.g. time-trade-off, 
standard gamble utility values; 
condition-specific outcome measures; 
functional outcome measures 
English version of PROMS 
Outcome measures of patient satisfaction 
or experience, or outcome measures 
obtained from proxies, carers or 
health providers 
Non-English versions of PROMS 
 
 
Study type Published validation studies, other than 
linguistic validation of English 
versions of relevant PROMS 
Publication in English 
Unpublished studies 
Studies of linguistic validation of PROMS 
Review articles, letters, commentaries, 
abstracts 
Non-English publications 
PROM, patient-reported outcome measure; EQ, EuroQol; SF, Short Form. 
  
Table 2 Psychometric criteria used to assess the quality of the patient-reported outcome measures 
included in this study 
 
 
  
Domain Criteria 
Test±retest reliability 
 
Test±retest: the intraclass correlation/weighted N VFRUHVKRXOGEH 0.70 for group comparisons  
DQGLIVFRUHVDUHJRLQJWREHXVHGIRUGHFLVLRQVDERXWDQLQGLYLGXDOEDVHGRQWKHLU
score19 
 The mean difference (paired t test or Wilcoxon signed-rank test) between time points 1 and 2, 
and the 95% c.i. should also be reported12,13 
Internal consistency 
 
$&URQEDFK¶VDVFRUHRI 0.70 is considered good, DQGLWVKRXOGQRWH[FHHG 0.92 for group 
comparisons as this is taken to indicate that items in the scale could be redundant.  Item total 
FRUUHODWLRQVVKRXOGEH 0.2014,20 
Content validity 
 
This is assessed qualitatively during the development of an instrument. To achieve good content 
validity, there must be evidence that the instrument has been developed by consulting 
patients and experts as well as undertaking a literature review20 
Patients should be involved in the development stage and item generation. The opinion of patient 
representatives should be sought on the constructed scale12±14 
Construct validity A correlation coHIILFLHQWRI 0.60 is taken as strong evidence of construct validity. Authors 
should make specific directional hypotheses and estimate the strength of correlation before 
testing12±14 
Criterion validity 
 
A good argument should be made as to why an instrument is standard and correlation with the  
standard VKRXOGEH15,16,18,19 
Responsiveness 
 
There are a number of methods to measure responsiveness, including t tests, effect size, 
standardized response means or responsiveness statistics, *X\DWW¶s responsiveness index. 
There should be statistically significant changes in score of an expected magnitude21,22  
Floor and ceiling effects  A floor or ceiling effect is considered if 15% of respondents are achieving the lowest or the 
highest score on the instrument12,13 
Acceptability  
 
Acceptability is measured by the completeness of the data supplied; 80% of the data should be 
complete12 
Table 3 Studies reporting validation of patient-reported outcome measures in patients with varicose 
veins  
0HDQYDOXHVH[FHSWPHGLDQ3520SDWLHQW-reported outcome measure; PDVS, PROM 
development and validation study; AVVQ, Aberdeen Varicose Vein Questionnaire; SF-36®, 36-Item 
Short Form Survey; EVLA, endovenous laser ablation; UGFS, ultrasound-guided foam sclerotherapy; 
n.r., not reported; EMA, endovenous microfoam ablation; PEM, polidocanol endovenous microfoam; 
VVSymQ®, Varicose Veins Symptoms Questionnaire; RFA, radiofrequency ablation; SQOR-V, 
Specific Quality-of-life and Outcome Response ± Venous.  
  
Reference Country Treatment 
Type of study 
 
Sample 
size 
Age 
(years)* 
Men 
(%) 
Reported 
PROM(s) 
Timing o
PROM(s
assessmen
Garratt et al.25 UK Usual care PDVS 373 45.8 24 AVVQ/SF-36® Administer
once 
Garratt et al.26 UK Usual care PDVS 1700 42.7 33.5 SF-36® 2 weeks af
baseline
Garratt et al.27 UK Usual care PDVS 1700 47.9 39.8 SF-36® Baseline an
after 1 yea
Garratt et al.28 UK Usual care PDVS 373 45.8 46.1 AVVQ/SF-36® 2 weeks an
12 month
after baseli
Lattimer et al.29 UK EVLA versus 
UGFS 
RCT 100 n.r. 42 AVVQ Baseline, 
weeks and
months 
Lattimer et al.29 UK EVLA  versus 
UGFS 
RCT 
 
84 47.5 47.6 AVVQ Baseline, 
weeks and
months 
Paty et al.31 USA EMA and PEM RCT 395 49.6 26.78 VVSymQ® 
 
Baseline an
weeks (dail
Shepherd et al. 
32
 
UK RFA only PDVS 317 48.87 28.4 AVVQ, SQOR-
V 
Baseline an
weeks 
Wright et al. 33 USA EMA and PEM RCT 40 49.7 37.5 VVSymQ® Baseline an
weeks (dail
  
Table 4 Summary of the psychometric properties of patient-reported outcome measures in patients 
with VLU 
Reference 
Psychometric and operational criteria 
Internal 
consistency 
Test±
retest 
reliability 
Content 
validity 
Criterion 
validity 
Construct  
validity Responsiveness 
Floor/ 
ceiling 
effect Acceptability 
Generic PROMS    
SF-36®          
    Garratt et al.  + 0 ? 0 +/± +/± 0 + 
    Garratt et al.27  0 0 0 0 0 + 0 +/± 
Disease-specific PROMs 
AVVQ         
       Garratt et al. + 0 +/- + + 0 0 +/± 
       Garratt et al.28  0 + 0 0 0 + 0 +/± 
       Shepherd et al.32 0 ± 0 + ± +/± 0 +/± 
       Lattimer et al.29 0 0 0 0 0 + 0 0 
       Lattimer et al.30 0 0 0 0 0 ? 0 0 
VVSymQ®         
    Paty et al.31 + 0 0 + 0 + +/± + 
    Wright et al.33 + + + +/± + + 0 + 
SQOR-V         
   Shepherd et al.32 0 ± 0 + ± +/± 0 +/± 
0, Not reported (no evaluation completed); ±, evidence not in favour; +/-, weak evidence; +, 
evidence in favour; ?, methodology questionable. PROM, patient-reported outcome measure; 
SF-36®, 36-Item Short Form Survey; AVVQ, Aberdeen Varicose Vein Questionnaire; 
VVSymQ®, Varicose Veins Symptoms Questionnaire; SQOR-V, Specific Quality-of-life and 
Outcome Response ±Venous. 
 
 
 
 
 
 
 
